Adventist Health System of West, a covered entity under the Section 340B Drug Pricing Program, purchased drugs from major pharmaceutical manufacturers at prices it alleged were inflated above the statutory ceiling. Under the Section 340B Program, manufacturers agree to sell drugs to covered entities at discounted rates, and federal programs like Medicaid and Medicare reimburse these entities for the drug costs. Adventist filed a qui tam lawsuit under the False Claims Act, alleging that the manufacturers knowingly charged inflated prices, causing the federal and state governments to overpay through these reimbursement programs. The district court dismissed the case, relying on the Supreme Court's decision in Astra USA, Inc. v. Santa Clara Cnty., which held that covered entities cannot sue drug manufacturers directly for overcharging under Section 340B and must instead use an administrative dispute resolution process. The district court reasoned that Adventist's False Claims Act suit was merely a repackaged attempt to enforce Section 340B, which lacks a private right of action.
The Ninth Circuit reversed, holding that the False Claims Act provides an independent cause of action that is not barred by the lack of a private right of action under Section 340B. The court explained that while Astra precludes covered entities from suing for direct overcharges or breach of contract under Section 340B, Adventist was not seeking relief for itself as a covered entity. Instead, Adventist sued as a relator standing in the shoes of the government to recover losses incurred by the government due to fraudulent claims. The court emphasized that the False Claims Act imposes liability on anyone who knowingly presents a false claim for payment to the government, regardless of whether the underlying statute (Section 340B) lacks a private right of action. The court distinguished Astra by noting that Adventist's suit was not 'in essence' a suit to enforce Section 340B or the pharmaceutical pricing agreements. Rather, it was a claim that manufacturers submitted false records to the government, causing it to pay more than it should have. The court reasoned that barring such claims would undermine the False Claims Act, which is intended to reach all types of fraud resulting in financial loss to the government. The court also found that Adventist plausibly pleaded falsity, alleging that manufacturers charged prices that bore no relation to the statutory formula and that the government was misled into overpaying. The court rejected the argument that the 2019 HRSA rule was necessary to establish the pricing requirement, noting that the statutory formula itself mandated penny pricing when the ceiling price fell to zero.
The decision allows qui tam relators to pursue False Claims Act claims against drug manufacturers for alleged Section 340B pricing fraud without being barred by the Astra precedent. This opens the door for private enforcement of drug pricing fraud that harms government reimbursement programs, potentially leading to significant treble damages and penalties. The case is remanded to the district court for further proceedings on the merits of the False Claims Act claims, meaning the parties will now proceed to discovery and trial on the allegations of fraud.